Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Mitoxantrone
Drug ID BADD_D01480
Description An anthracenedione-derived antineoplastic agent.
Indications and Usage For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
Marketing Status approved; investigational
ATC Code L01DB07
DrugBank ID DB01204
KEGG ID D08224
MeSH ID D008942
PubChem ID 4212
TTD Drug ID D0R3JB
NDC Product Code 61703-343
UNII BZ114NVM5P
Synonyms Mitoxantrone | Mitozantrone | DHAQ | NSC-279836 | NSC 279836 | NSC279836 | NSC-287836 | NSC 287836 | NSC287836 | NSC-299195 | NSC 299195 | NSC299195 | NSC-301739 | NSC 301739 | NSC301739 | NSC-301739D | NSC 301739D | NSC301739D | Mitroxone | Pralifan | CL-232325 | CL 232325 | CL232325 | Mitoxantrone Acetate | Acetate, Mitoxantrone | Mitoxantrone Hydrochloride | Hydrochloride, Mitoxantrone | Novantrone | Ralenova | Novantron | Onkotrone
Chemical Information
Molecular Formula C22H28N4O6
CAS Registry Number 65271-80-9
SMILES C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Enteritis07.08.03.002--
Erythema23.03.06.001---
Extravasation08.01.03.008---
Eye disorder06.08.03.001---
Fatigue08.01.01.002--
Febrile neutropenia01.02.03.002; 08.05.02.0040.000336%
Feeling abnormal08.01.09.014---
Foot and mouth disease07.05.07.010; 11.05.04.020; 23.11.05.002---
Fungal infection11.03.05.001---
Fungal skin infection11.03.05.002; 23.11.03.006---
Gamma-glutamyltransferase increased13.03.04.024--
Gastrointestinal disorder07.11.01.001---
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.009---
Gastrointestinal pain07.01.05.005--
Granulocytes abnormal13.01.06.034---
Granulocytopenia01.02.03.003---
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.047--
Haemoglobin13.01.05.018---
Haemoglobin decreased13.01.05.003---
Haemorrhage intracranial17.08.01.008; 24.07.04.003--
Headache17.14.01.001--
Hemiparesis17.01.04.0010.000112%
Hepatitis09.01.07.004---
Hepatomegaly09.01.05.001---
Hepatotoxicity09.01.07.009; 12.03.01.0080.000224%-
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hyperkalaemia14.05.03.001--
Hyperphosphataemia14.04.03.007--
Hypersensitivity10.01.03.003--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene